Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biodesign® Otologic Graft in Canal Wall Down Mastoidectomy
NCT03902938Phase 4Withdrawn
- Sponsor
- Henry Ford Health
- Start
- Oct 2018
- Primary completion
- Jul 2022
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial (2 arms), sponsored by Henry Ford Health. Primary endpoint: Epithelialization of the canal wall down mastoid cavity at 6 months. Planned start Oct 2018; status: withdrawn.
Beyond the preview
Go deeper on NCT03902938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03902938.